Abstract
Evidence-Based Answer Combining angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) reduces admissions for heart failure in patients with congestive heart failure (CHF), but with an increased rate of adverse effects and no reduction in mortality or overall hospitalization rates (SOR: A, meta-analysis of RCTs). Combination therapy is not superior to monotherapy in preventing serious adverse outcomes in patients with known vascular disease or diabetes with end-organ damage and has higher rates of hypotension, diarrhea, and renal impairment (SOR: B, 1 RCT).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
